Google Play icon

Case Western Reserve and Haima Therapeutics sign option license to develop SynthoPlate

Posted June 8, 2018

Case Western Reserve University and Haima Therapeutics LLC, a Cleveland-based biotechnology company, have signed a two-year option to license a hemostatic nanotechnology, called SynthoPlate, to prevent and treat bleeding complications from trauma, low platelet counts and surgery.

More than 2 million units of platelets are transfused annually in the United States to treat such complications and various blood-related ailments.

However, natural platelet products, which depend entirely on human donors, suffer from many issues, including: limited supply, short shelf life (three to five days) due to a high risk of bacterial contamination, minimal portability, the need for blood typing/matching and potentially severe biologic side effects.

To address these issues, Anirban Sen Gupta, a professor in Case Western Reserve’s Department of Biomedical Engineering, has spent nearly a decade developing synthetic nanoparticles that can mimic platelets’ abilities to clot at the site of a bleeding injury.

The nanoparticles can be injected intravenously and potentially act as a platelet surrogate to prevent or treat bleeding when natural platelet products are unavailable or to reduce the need for donor platelet transfusion.

“Outside of large blood banks and trauma centers, platelet products are rarely available. It is an even bigger challenge to get donor platelets to our military in the field where heavy bleeding injuries are frequent,” Sen Gupta said. “Our nanoparticle technology can be used in civilian and military scenarios of traumatic non-compressible bleeding where donor platelets are not readily available. This has been the motivation behind the research on platelet surrogates in my laboratory, and SynthoPlate is a technology that stemmed from it.”

The two-year option to license agreement, managed through Case Western Reserve’s Technology Transfer Office (TTO), will allow pre-clinical testing of the technology, including safety profiling and feasibility of scaled-up manufacturing.

“This technology has been well-positioned for translation through the support it has received from a number of our research grants,” said Stephanie Weidenbecher, TTO’s senior licensing manager.

“We are excited to work with Dr. Sen Gupta to advance this highly promising technology toward the clinic,” said Christa Pawlowski, co-founder and chief scientific officer at Haima Therapeutics. “Our goal is to provide a product that can address the real, unmet needs of patients with bleeding complications.”

Source: Case Western Reserve University

Featured news from related categories:

Technology Org App
Google Play icon
84,698 science & technology articles

Most Popular Articles

  1. Real Artificial Gravity for SpaceX Starship (September 17, 2019)
  2. Top NASA Manager Says the 2024 Moon Landing by Astronauts might not Happen (September 19, 2019)
  3. How social media altered the good parenting ideal (September 4, 2019)
  4. What's the difference between offensive and defensive hand grenades? (September 26, 2019)
  5. Just How Feasible is a Warp Drive? (September 25, 2019)

Follow us

Facebook   Twitter   Pinterest   Tumblr   RSS   Newsletter via Email